Back to search

Peptide record

TPDB91988

CA-MA Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91988
CA-MA
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab Antifungipept CAFPdb
standard
No
A 20-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KWKLFKKIGIGKFLHSAKKF-NH2
Physicochemical Analysis
C120H190N30O22
RNDCEQMPTYV
K
2405.02
11.29
8
0
9
+7
0.89
-0.310
83.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
228.69
1
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
1
H
2
I
2
L
7
K
0
M
3
F
0
P
1
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 1 I: 2 L: 2 K: 7 M: 0 F: 3 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
20
C120H190N30O22
2405.02
11.29
+7
0.89
-0.310
Amidation
L
Linear
Free
Antibacterial Antimicrobial and Anticancer, antibacterial, antifungal
Ceropin-Magainin hybrid peptides Ceropin A-Magainin 2 Ceropin-Melittin hybrid
Evidence Records 13 records
Evidence 1 Activity

Activity

IC50
IC50=65 µM
Anticancer
65 µM

Target

Leukemia Cancer
K-562
Blood

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=60 µM
Anticancer
60 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 3 Activity

Activity

IC50
IC50=30 µM
Anticancer
30 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 4 Activity

Activity

IC50
IC50=44 µM
Anticancer
44 µM

Target

Breast Cancer
MDA-MB-361
Breast

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 5 Activity

Activity

IC50
IC50=15.8 µM
Anticancer
15.8 µM

Target

Lung Cancer
NCI-H69
Lung

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1997
Evidence 6 Activity

Activity

IC50
IC50=16.1 µM
Anticancer
16.1 µM

Target

Lung Cancer
NCI-H128
Lung

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1997
Evidence 7 Activity

Activity

IC50
IC50=15.8 µM
Anticancer
15.8 µM

Target

Lung Cancer
NCI-H146
Lung

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1997
Evidence 8 Activity

Activity

~90% survival rate at 10 µM
Anticancer

Target

Lung Cancer
Calu-6
Lung

Assay & Model

MTT/MTS assay

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
US_6800727_B2
Evidence 9 Activity

Activity

<20% survival rate at 100 µM
Anticancer

Target

Lung Cancer
Calu-6
Lung

Assay & Model

MTT/MTS assay

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
US_6800727_B2
Evidence 10 Activity

Activity

100% survival rate at 10 µM
Anticancer

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
US_6800727_B2
Evidence 11 Activity

Activity

0% survival rate at 100 µM
Anticancer

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
US_6800727_B2
Evidence 12 Activity

Activity

~80% survival rate at 10 µM
Anticancer

Target

Gastric Cancer
SNU-601
Stomach

Assay & Model

MTT/MTS assay

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
US_6800727_B2
Evidence 13 Activity

Activity

10% survival rate at 100 µM
Anticancer

Target

Gastric Cancer
SNU-601
Stomach

Assay & Model

MTT/MTS assay

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
US_6800727_B2